Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study

Area of Science:

• Oncology
• Immunotherapy
• Dermatology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer.
• Avelumab, an anti-PD-L1 antibody, is approved for MCC but has limitations as monotherapy.
• Novel therapeutic combinations are needed for patients with refractory MCC.

Observation:

• A 71-year-old male patient with MCC showed a partial response to avelumab monotherapy.
• The addition of N-803 (an IL-15 superagonist) and nab-paclitaxel led to a significant tumor burden reduction.
• The patient achieved and maintained a complete response (CR) on subsequent treatment with avelumab and N-803.

Findings:

• Combination therapy with avelumab, N-803, and nab-paclitaxel resulted in a complete response in a patient with advanced MCC.
• Nab-paclitaxel was discontinued after achieving CR, with continued response maintained by avelumab and N-803.
• This case demonstrates the potential efficacy of combining immune checkpoint inhibitors with IL-15 agonists and chemotherapy.

Implications:

• This combination therapy may represent a viable treatment strategy for MCC patients unresponsive to avelumab monotherapy.
• Targeting immune pathways with agents like N-803 alongside checkpoint inhibitors could enhance anti-tumor responses.
• Further investigation into this combination regimen is warranted for optimizing MCC treatment outcomes.